How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

13,996 results for

E/M Medical Decision Making

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. Focused Update of the 2017 ACC Expert Consensus Decision Pathway on the Management of Mitral Regurgitation

), and the results of landmark randomized controlled trials (RCTs) (4,5) published in 2018. Additional clinical context and practical advice are provided for medical and surgical decision making in complex patient scenarios. 2. METHODS The writing committee for this updated 2019 ECDP was formed in 2018. As outlined in Table 1, several revisions have been made to the 2017 ECDP in response to rapid developments in the field and the March 2019 FDA approval of an edge-to-edge transcatheter repair system (...) Focused Update of the 2017 ACC Expert Consensus Decision Pathway on the Management of Mitral Regurgitation Journal Pre-proof 2020 Focused Update of the 2017 ACC Expert Consensus Decision Pathway on the Management of Mitral Regurgitation Robert O. Bonow, MD, MS, MACC Chair, Writing Committee, Patrick T. O’Gara, MD, MACCVice-chair, Writing Committee, David H. Adams, MD, FACC, Writing Committee, Vinay Badhwar, MD, FACC, Writing Committee, Joseph E. Bavaria, MD, FACC, Writing Committee, Sammy

2020 American College of Cardiology

62. Knowledge-based clinical decision support systems

Assessment | 25 References 1. Bright TJ, Wong A, Dhurjati R, Bristow E, Bastian L, Coeytaux RR, et al. Effect of clinical decision support systems: a systematic review. Ann Intern Med. 2012;157(1):29-43. 2. Jia P, Zhang L, Chen J, Zhao P, Zhang M. The effects of clinical decision support systems on medication safety: an overview. PLoS ONE. 2016;11(12):e0167683. 3. TechTarget. Clinical decision support systems (CDSS). 2018 [cited 2020 Jan 30]; Available from: https://searchhealthit.techtarget.com (...) Psychiatry. 2017;26(11):1309-17. 11. Marasinghe KM. Computerised clinical decision support systems to improve medication safety in long-term care homes: a systematic review. BMJ Open. 2015;5(5):e006539. 12. Monteiro L, Maricoto T, Solha I, Ribeiro-Vaz I, Martins C, Monteiro-Soares M. Reducing potentially inappropriate prescriptions for older patients using computerized decision support tools: systematic review. J Med Internet Res. 2019;21(11):e15385. 13. NICE. Medicines optimisation: the safe

2020 SHTG Advice Statements

63. Rammya Mathew: Acknowledging clinician bias in shared decision making Full Text available with Trip Pro

decision between patient and doctor. In practice this might involve the use of shared decision aids, employing the use of multidisciplinary decision-making in patients with complex multimorbidity , and most of all, keeping the person in mind rather than treating single diseases based solely on clinical guidelines which often fail to take account of the wider bio-psychosocial model. [2] Rammya Mathew is a GP at Wembley Park Drive Medical Centre and Quality Improvement Clinical Lead, Islington Federation (...) Rammya Mathew: Acknowledging clinician bias in shared decision making Rammya Mathew: Acknowledging clinician bias in shared decision making - The BMJ ---> A piece of improvement work I’ve been involved in has thrown up some questions for me around anticoagulation in atrial fibrillation (AF). indicates that we are undertreating people with AF in terms of anticoagulation, and as a result, they are unnecessarily being put at risk of having a stroke. [1] Looking at this in more detail, it seems

2018 The BMJ Blog

64. Extract from Cannabis sativa (spasticity due to multiple sclerosis) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)

Extract from Cannabis sativa (spasticity due to multiple sclerosis) - Benefit assessment according to §35a Social Code Book V (expiry of the decision) Extract 1 Translation of the executive summary of the dossier assessment Extrakt aus Cannabis sativa (Spastik aufgrund von multipler Sklerose) – Nutzenbewertung gemäß § 35a SGB V (Ablauf Befristung) (Version 1.0; Status: 26 July 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG (...) to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A18-27 Extract from Cannabis sativa (spasticity due to multiple sclerosis) – Benefit assessment according to §35a Social Code Book V 1 (expiry of the decision) Extract of dossier assessment A18-27 Version 1.0 Extract from Cannabis sativa (spasticity due to multiple sclerosis) 26 July 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

65. Varicella Zoster Virus glycoprotein E antigen (Shingrix) - Herpes Zoster

Varicella Zoster Virus glycoprotein E antigen (Shingrix) - Herpes Zoster 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 25 January 2018 EMA/88588/2018 Committee for Medicinal Products for Human Use (CHMP) Assessment report Shingrix International non-proprietary name: herpes zoster vaccine (recombinant, adjuvanted) Procedure (...) Mediated Immunity CPV Continued Process Verification CSR Clinical Study Report DOPC Dioleoyl Phosphatidylcholine ELISA Enzyme-Linked Immunosorbent Assay EMA European Medicines Agency, EU EOS End of Study EPC End-of-Production Cell bank EU European Union FB Final Bulk FC Final Container FDA Food and Drug Administration, US FLU-D-QIV GSK’s unadjuvanted quadrivalent seasonal influenza vaccine FP Finished Product GCP Good Clinical Practice gE Glycoprotein E GM Geometric Mean GMP Good Manufacturing Practice

2018 European Medicines Agency - EPARs

66. Translation of a C. difficile Treatment Clinical Pathway Into Machine-Readable Clinical Decision Support Artifacts Prototyped for Electronic Health Record Integration

of clinical judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information, i.e., in the context of available resources and circumstances presented by individual patients. This report is made available to the public under the terms of a licensing agreement between the author and the Agency for Healthcare Research and Quality. This report may be used and reprinted (...) technology may not be able to fully access information in this report. For assistance contact EPC@ahrq.hhs.gov. Suggested citation: Michel J, Flores E, Mull N, Tsou AY. Translation of a Clinical Pathway for C. Difficile Treatment Into a Machine-Readable Clinical Decision Support Artifact Prototyped for Electronic Health Record Integration. Methods Research Report. (Prepared by the ECRI Institute –Penn Medicine Evidence-based Practice Center under Contract No. 290-2015-00005- I.) AHRQ Publication No. 20

2019 Effective Health Care Program (AHRQ)

67. Methodology for Creating Expert Consensus Decision Pathways

; Michael E. DeBakey Medical Center—Director, Cardiac Care Unit Melissa Magwire Content Reviewer—Expert Consensus Decision Pathway Writing Committees Shawnee Mission Endocrinology & Diabetes—Clinical Supervisor Catherine M. Otto Content Reviewer—Expert Consensus Decision Pathway Writing Committees J. Ward Kennedy-Hamilton Endowed Chair in Cardiology—Editor-in-Chief, Heart; University of Washington—Professor of Medicine Sarah A. Spinler Content Reviewer—Roundtable Planning Committee Philadelphia College (...) None None None Dharam J. Kumbhani UT Southwestern Medical Center— Assistant Professor, Interventional Cardiology, Department of Internal Medicine n ACC* None None None None None Thomas M. Maddox BJC HealthCare/Washington University School of Medicine—Executive Director, Healthcare Innovation Lab; Washington University School of Medicine—Professor of Medicine (Cardiology) None None None None n BJC Healthcare/ Washington University School of Medicine* None Joseph E. Marine Johns Hopkins School

2019 American College of Cardiology

68. E/M Emergency Services

E/M Emergency Services E/M Emergency Services Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 E/M Emergency Services E/M Emergency (...) Services Aka: E/M Emergency Services , E/M Emergency , CPT 99281 , CPT 99282 , CPT 99283 , CPT 99284 , CPT 99285 II. Indication Emergency Department Services III. Approach Know your intended level of service from the start and document to meet that level of service HPI Code 99281 - 99283: Requires 1 of 8 component Code 99284 - 99285: Requires 4 of 8 components ROS Code 99281: Requires 0 component Code 99282 - 99283: Requires 1 component Code 99284: Requires 2 components Code 99285: Requires 10

2018 FP Notebook

69. Responsible use of high-risk medical devices: the example of 3D printed medical devices

” Creative Commons Licence http://kce.fgov.be/content/about-copyrights-for-kce-publications. How to refer to this document? Vinck I, Vijverman A, Vollebregt E, Broeckx N, Wouters K, Piët M, Bacic N, Vlayen J, Thiry N, Neyt M.Responsible use of high-risk medical devices: the example of 3D printed medical devices. Health Technology Assessment (HTA) Brussels: Belgian Health Care Knowledge Centre (KCE). 2018. KCE Reports . D/2018/10.273/03. This document is available on the website of the Belgian Health Care (...) ) Participation in scientific or experimental research as an initiator, principal investigator or researcher: Philip Tack (IWT Project ‘Roadmap’ about medical 3D Printing (part Health economy: PHD traject), Jan Schrooten (Projects KU Leuven – generative medicine / VLAIO feasibility assessment Antheron BV.B.A.), Stefaan Nijs (3D modelling in shoulder althea prof. (UZ Leuven – KU Leuven)) A grant, fees or funds for a member of staff or another form of compensation for the execution of research described above

2018 Belgian Health Care Knowledge Centre

70. Intrapartum care for women with existing medical conditions or obstetric complications and their babies

://www.nice.org.uk/terms-and- conditions#notice-of-rights). Last updated April 2019 Page 6 of 96Recommendations Recommendations People have the right to be involved in discussions and make informed decisions about their care, as described in your care. Making decisions using NICE guidelines explains how we use words to show the strength (or certainty) of our recommendations, and has information about prescribing medicines (including off-label use), professional guidelines, standards and laws (including (...) on consent and mental capacity), and safeguarding. Supporting women to make decisions about their care is particularly important during the intrapartum period. Healthcare professionals should ensure that women have the information they need to make decisions and to give consent in line with General Medical Council (GMC) guidance and the 2015 Montgomery ruling. 1.1 Information for women with existing medical conditions 1.1.1 Clarify with women with existing medical conditions whether and how they would

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

71. External stimulation of the trigeminal nerve for the prevention and acute treatment of episodic and chronic migraine. Decision Support Document 114.

the small size of the highly selective sample of patients included in the evidence base (as compared to the large burden of disease that migraine creates), the conclusions about effectiveness and the positive safety profile appear to be inflated. The target population of e-TNS are not only patients refractory to medication, but mainly drug responsive patients, which makes replacing the use of medication a main objective of e-TNS. That is why larger controlled trials with best practice interventions (...) External stimulation of the trigeminal nerve for the prevention and acute treatment of episodic and chronic migraine. Decision Support Document 114. External stimulation of the trigeminal nerve for the prevention and acute treatment of episodic and chronic migraine - Repository of AIHTA GmbH English | Browse - - - External stimulation of the trigeminal nerve for the prevention and acute treatment of episodic and chronic migraine Stanak, M. and Wolf, S. and Jagoš, H. (2018): External stimulation

2018 Austrian Institute of Health Technology Assessment

72. MammaPrint test for personalised management of adjuvant chemotherapy decisions in early breast cancer

patients KCE Report 298 ¦ SCIENTIFIC REPORT a http://www.eunethta.eu/ 1 INTRODUCTION AND SCOPE Gene expression profiling (GEP) tests aim to improve decision-making related to adjuvant chemotherapy treatment for women with early breast cancer. In 2014, KCE performed a rapid HTA on this topic 1 and concluded that there were no data on the clinical utility of such tests and that an update of the review should be performed as soon as RCT results on such aspect became available. Following the publication (...) , decisions on when the use of adjuvant chemotherapy is appropriate and necessary to minimise the risk of recurrence and improve the prognosis of ER+, HER2- early breast cancer patients with up to 3 affected lymph nodes (i.e. the subject of interest of this review), remain in some cases challenging. d http://www.predict.nhs.uk/ e http://www.pmidcalc.org 8 MammaPrint ® test in adjuvant chemotherapy decisions for early breast cancer patients KCE Report 298 3 MAMMAPRINT® IN EARLY BREAST CANCER 3.1 MammaPrint

2018 Belgian Health Care Knowledge Centre

73. Don’t throw the E&M baby out with the bath water: the proposed CMS changes

, physicians often must document information that is not pertinent to the visit but must be present to choose the code, such as examining and documenting a detailed examination with at least 12 bullets from any organ system to bill a 99203. Instead, what CMS is proposing is that a physician may pick the E&M code based on the current system, the amount of time spent with the patient, or solely based on medical decision-making (MDM) guidelines for the code. The option to choose time would change (...) in that it would be based completely on total face-to-face time with the patient and not limited to visits where over 50 percent of the visit is counseling and/or coordination of care as it is at present. As an example of using MDM as the sole factor, if you have a patient with type II diabetes, hypertension, and hyperlipidemia, you review their pertinent history, review their recent labs, and advise them to continue their medications, you have moderate complexity medical decision-making and can choose 99214

2018 KevinMD blog

74. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. Full Text available with Trip Pro

) and is not enhanced by nodal positivity. However, in an underpowered exploratory analysis this benefit appears to be age-dependent, as it is only seen in women younger than 50 years where it reaches a clinically relevant threshold of 5 percentage points. Although, possibly due to chemotherapy-induced ovarian function suppression, it should be part of informed, shared decision making. Further study is needed in younger women, who might need reinforced endocrine therapy to forego chemotherapy. Funding: European (...) Commission Sixth Framework Programme. Copyright © 2021 Elsevier Ltd. All rights reserved. Similar articles Prat A, Guarneri V, Paré L, Griguolo G, Pascual T, Dieci MV, Chic N, González-Farré B, Frassoldati A, Sanfeliu E, Cejalvo JM, Muñoz M, Bisagni G, Brasó-Maristany F, Urso L, Vidal M, Brandes AA, Adamo B, Musolino A, Miglietta F, Conte B, Oliveira M, Saura C, Pernas S, Alarcón J, Llombart-Cussac A, Cortés J, Manso L, López R, Ciruelos E, Schettini F, Villagrasa P, Carey LA, Perou CM, Piacentini F

2021 EvidenceUpdates

75. PROTOCOL: The Effects of School-Based Decision Making on Educational Outcomes in Low and Middle Income Contexts: A Systematic Review Full Text available with Trip Pro

PROTOCOL: The Effects of School-Based Decision Making on Educational Outcomes in Low and Middle Income Contexts: A Systematic Review PROTOCOL: The Effects of School‐Based Decision Making on Educational Outcomes in Low and Middle Income Contexts: A Systematic Review - Carr‐Hill - 2014 - Campbell Systematic Reviews - Wiley Online Library Working off-campus? Learn about our By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search (...) term PROTOCOL Open Access PROTOCOL: The Effects of School‐Based Decision Making on Educational Outcomes in Low and Middle Income Contexts: A Systematic Review Professor of Education in Developing Countries +44 (0)20 7612 6631 Institute of Education, 20 Bedford Way, London, WC1H 0AL UK Lecturer in Education & International Development +44 (0)20 3073 8314 Institute of Education, 20 Bedford Way, London, WC1H 0AL UK Senior Lecturer in Education & International Development +44 (0)20 7331 5201 Institute

2014 Campbell Systematic Reviews

76. Added value of using gene-expression signature for adjuvant chemotherapy decisions in early breast cancer

Added value of using gene-expression signature for adjuvant chemotherapy decisions in early breast cancer Nov2015 © EUnetHTA, 2015. Reproduction is authorised provided EUnetHTA is explicitly acknowledged EUnetHTA Joint Action 3 WP4 Rapid assessment of other technologies using the HTA Core Model ® for Rapid Relative Effectiveness Assessment MammaPrint ® Added value of using the gene expression signature test MammaPrint® for adjuvant chemotherapy decision-making in early breast cancer Project ID (...) , patients can be divided into low- and high-risk groups, which in turn supports clinical decision- making for adjuvant treatment. MammaPrint ® has been prospectively validated for use in early- stage breast cancer patients with tumours 5% or HR 5% at =3 years follow-up and a GRADE B survival improvement as between 3% and 5%. In the case that mature survival data is not available, GRADE A clinical benefit is assigned when DFS improvements are found in which the HR is 70 19 (0.7) 11 (1.9) 16 (1.0) 10 (0.6

2018 EUnetHTA

77. Clinical effectiveness of compounded topical medications in oral medicine: a meta-analysis Full Text available with Trip Pro

of compounded topical medications in oral medicine: a meta-analysis Views: | Downloads: | Citations: 0 Her Basuki Margono 1 , Irna Sufiawati 2 1 Oral Medicine Residency Program, Faculty of Dentistry, Padjadjaran University , Views:454 | Downloads:82 | Citations: 0 | Received: 16 Oct 2019 | First Decision: 11 Nov 2019 | Revised: 14 May 2020 | Accepted: 21 Jul 2020 | Published: 19 Aug 2020 Academic Editor: Letizia Perillo | Copy Editor: Cai-Hong Wang | Production Editor: Jing Yu © The Author(s) 2020. Open (...) Clinical effectiveness of compounded topical medications in oral medicine: a meta-analysis Clinical effectiveness of compounded topical medications in oral medicine: a meta-analysis Clinical efficacy, drug compounding, meta-analysis, oral medicine, topical administration Search in all OAE Journals Stomatological Disease and Science sdsjournal.com Hot Keywords Navigation Bar Menu Article Stomatological Dis Sci 2020;4:3. © The Author(s) 2020. Open Access Meta-Analysis Clinical effectiveness

2020 Stomatological Disease and Science

78. Decision Making in Advanced Heart Failure

Decision Making in Advanced Heart Failure AHA Scientific Statement Decision Making in Advanced Heart Failure A Scientific Statement From the American Heart Association Endorsed by Heart Failure Society of America, American Association of Heart Failure Nurses, and Society for Medical Decision Making Larry A. Allen, MD, MHS, Co-Chair; Lynne W. Stevenson, MD, Co-Chair; Kathleen L. Grady, PhD, APN, FAHA, Co-Chair; Nathan E. Goldstein, MD; Daniel D. Matlock, MD, MPH; Robert M. Arnold, MD; Nancy R (...) therapeutic options may be considered unreasonable and there- fore independent of patient demands, although situations of medicalfutilityarerelativelyrare. 6 Althoughnotallpatientswill be able to clearly articulate decisions that are congruent with their stated goals, shared decision making aims to ensure that patients’ values, goals, and preferences are explored and incor- porated into the medical decision-making process. Patient-centered medicine has been suggested as the next phaseinhealthcare. 11

2012 American Heart Association

79. e-income countries from a provider’s perspective: a systematic review Full Text available with Trip Pro

), in reducing these maternal and newborn morbidities and mortalities has been reported in the literature. However, in addition to considerations on effectiveness in decision-making to provide these services, planners and policy makers need evidence on the cost of their provision. Among experts, the preference for costing health services is to use robust country-specific data collected from representative populations for costing health services, more so for maternal health services. Such cost data which (...) ), as opposed to actual costs as well as studies published year 2000 onwards using cost data preceding year 2000 were excluded. This decision was made in consideration of the marked difference in health financing approach after year 2000. Finally, we excluded studies that focused on specialist services such as ANC for HIV-positive mothers as they would typically include additional tests and medicines targeted at prevention of mother-to-child transmission. Data extraction Guidance on approach and content

2020 BMJ global health

80. A Conceptual Model of the Challenges of Social Media Big Data for Citizen e-Participation: A Systematic Review Full Text available with Trip Pro

decision-making for service delivery in CzRM. It is believed that the demand for SMA adoption will increasingly rise. However, the reality of social media Big Data comes with the challenges of analysing it in a way that brings Big Value. The purpose of this paper is to identify the challenges of social media Big Data Analytics (BDA) and to incorporate these in a conceptual model that can be used by governments to support the e-participation of citizens. The model was developed through a systematic (...) challenges: privacy, security, data governance, data and information sharing, cost/operational expenditures, and data ownership. Keywords Citizen Relationship Management Data lifecycle Big Data Big Data Analytics e-Participation Social Media Analytics conference paper PDF 1 Introduction Social Media Analytics (SMA) can provide a decision-making framework that can influence the quality of social media Big Data for citizen e-participation; however, this attempt will need well-defined tools and guidelines

2020 Responsible Design, Implementation and Use of Information and Communication Technology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>